Europe’s next generation of health innovation start-ups recognised
Europe’s highest-potential life science and healthtech start-ups have today been named as winners of the 2024 EIT Health Catapult programme, run with the partners BioRN, Medical Valley, and Cap Digital.
A jury of industry leaders, academics, and health innovation investors selected the winners from nine finalists at the health.tech conference in Munich.
This year’s winners are:
- Life Science: CELEX Oncology (UK), which is treating invasive and metastatic cancer via transformation
- HealthTech: Acorai (Sweden), which is developing the first handheld, non-invasive ICP monitor
- Audience-voted Alex Casta Award: Dymium (Germany), which is pioneering magnetism-based residue-free extraction of kidney stones
In addition to the recognition afforded the winners and finalists, industry leaders from EIT Health Catapult’s Industry partners AstraZeneca, AWS for Life Sciences, eg technology, and Lusíadas Saúde, have committed to providing additional support to select participants and winners.
Winners join the ranks of Europe’s best-funded health innovators
The Catapult programme is backed by a community of more than 400 investors and 2 500 healthcare professionals, and aims to accelerate the growth of European health start-ups through access to expertise and financing.
Since the programme’s launch in 2016, Catapult alumni have gone on to collectively raise more than EUR 550 million through grants, funding, and acquisitions. Previous investors and healthcare relevant stakeholders that have acquired or invested in semi-finalists and finalists include industry giants Alira Health, BioNTech, Exact Sciences, Jeito, 4BIO, and 10x Genomics.
Catapult alumni include many of biotech, medtech, and digital health’s best-funded and most acclaimed start-ups and scale-ups, including ADVITOS, AZmed, Cartana, deepeye, inHEART, Leuko, Limula, Methinks, Mimark, neuroClues, OmicEra, Peptomyc, PhagoMed, SolasCure, SparingVision, StemSight, Surge, and Xund.
Every year, EIT Health Catapult discovers start-ups from across Europe that have the potential to positively change the lives of millions of people around the world. Having supported our alumni in raising well over half a billion euros in investment is testament not only to the work of EIT Health Catapult, but also the talent, vision and innovative thinking of the European health-tech space. Announcing CELEX Oncology, Acorai, and Dymium as the three primary winners of the 2024 edition of the programme is yet another step on the journey of European healthcare innovation, that we at EIT Health are as proud as ever to be backing.
Jean-Marc Bourez, CEO of EIT Health
Industry leaders provide support to finalists and winners
AstraZeneca will provide finalists Acorai and Exhalation Technology with fast track into AstraZeneca’s BeyondVenture Programme and access to a tailored mentoring programme with industry experts.
Amazon Web Services will provide Activate l Credits for use on the AWS Cloud for all semifinalists and finalists, as well as visibility on AWS media channels and technical and business development office hours for Acorai.
eg technology will provide technical consultancy to three Healthtech start-ups: Plio Surgical (five days); Medicud (three days); Dymium (two days).
Lusíadas Saúde will offer Digistain, Acorai, and Five Lives pilots at Lusiadas Group hospitals plus clinical/technological transfer consultancy and data protection and cybersecurity in healthcare advice.
The winner of the audience-selected Alex Casta Award will see its company logo illuminated on the Nasdaq Tower in New York’s Time Square.
Share this page
